Journal
JOURNAL OF CELL BIOLOGY
Volume 188, Issue 6, Pages 759-768Publisher
ROCKEFELLER UNIV PRESS
DOI: 10.1083/jcb.200910104
Keywords
-
Categories
Funding
- National Cancer Institute Bioengineering Research [CA-122427]
- Innovator Award from the Department of Defense [W81XWH-08-1-0727]
- National Science Foundation [DMR-0806859]
- National Institutes of Health [U54 CA-119335]
- Division Of Materials Research
- Direct For Mathematical & Physical Scien [0806859] Funding Source: National Science Foundation
Ask authors/readers for more resources
The various types of cells that comprise the tumor mass all carry molecular markers that are not expressed or are expressed at much lower levels in normal cells. These differentially expressed molecules can be used as docking sites to concentrate drug conjugates and nanoparticles at tumors. Specific markers in tumor vessels are particularly well suited for targeting because molecules at the surface of blood vessels are readily accessible to circulating compounds. The increased concentration of a drug in the site of disease made possible by targeted delivery can be used to increase efficacy, reduce side effects, or achieve some of both. We review the recent advances in this delivery approach with a focus on the use of molecular markers of tumor vasculature as the primary target and nanoparticles as the delivery vehicle.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available